Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Expert Calls for Cross-Communication in NSCLC Treatment Decisions

March 1st 2018

Shirley Michelle Shiller, DO, discusses the application of biomarkers and the importance of educating practitioners on treatment advancements in NSCLC.

Strosberg Discusses Lutathera Approval, Remaining Challenges in NETs

March 1st 2018

Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.

Optimizing Genetic Testing Remains Challenge in Hematologic Malignancies

March 1st 2018

Andrew Laramore, MD, discusses the evolution of genetic testing in hematologic cancers and optimal methods of detection.

Expert Highlights Progress With Molecular Biomarkers in GI Cancers

March 1st 2018

Michael J. Pishvaian, MD, discusses expanded testing for biomarkers, using liquid biopsies to predict response to treatment, and the importance of identifying increasingly specific subsets of GI cancers to make treatment decisions.

Potentially Transformative Treatments Emerge in Pancreatic Cancer

March 1st 2018

Allyson Ocean, MD, discusses the development of novel therapeutic regimens in pancreatic cancer.

Expert Highlights Immunotherapy Use in Stage III NSCLC

February 28th 2018

Gary Schwartz, MD, discusses the significance of the PACIFIC trial and applications of immunotherapy for patients with stage III locally advanced disease.

Expert Highlights Developments in Myeloid Malignancies

February 27th 2018

Suman Kambhampati, MD, discusses available treatments for MDS and ongoing clinical trials investigating targeted treatments in myeloid malignancies.

Expert Highlights Promising Research in mCRC and Other GI Cancers

February 17th 2018

Michael A. Morse, MD, discusses key trials that have broadened the treatment landscape of mCRC, and other ongoing developments in gastrointestinal cancers.

Expert Discusses Docetaxel Versus Abiraterone in Hormone-Sensitive Prostate Cancer

February 14th 2018

William K. Oh, MD, discusses treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.

Updates in Targeted Combination Therapies for Melanoma

February 9th 2018

With the advent of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in melanoma physicians are no longer using BRAF inhibitors alone, but rather in combination with MEK inhibitors due to the improved efficacy.

Robotic Approaches Advancing Surgical Scope in Muscle-Invasive Bladder Cancer

February 7th 2018

William C. Huang, MD, discusses the transition from open cystectomy to minimally invasive robotic-assisted surgery in the management of muscle-invasive bladder cancer.

Balar Addresses Advances in Bladder and Kidney Cancer

February 5th 2018

Arjun V. Balar, MD, discusses the landscape of current and future standards of care for immunotherapy in bladder and kidney cancer.

Expert Highlights Significance of MRI-Guided Prostate Biopsies

February 1st 2018

Samir Taneja, MD, discusses his research on MRI-guided prostate biopsies and other modalities in development.

Remote Monitoring of Cardiovascular Symptoms in Patients With Cancer

February 1st 2018

Jean-Bernard Durand, MD, discusses implantable cardiac devices and how patients may be able to continue their treatment regimen.

Expert Shares Insight on Napabucasin Plus Pembrolizumab in mCRC

February 1st 2018

Akihito Kawazoe, MD, discusses the study of napabucasin plus pembrolizumab in mCRC.